You are here
Award Data
The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.
Download all SBIR.gov award data either with award abstracts (290MB)
or without award abstracts (65MB).
A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.
The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.
-
A Novel Technology to Disseminate WOOP (Wish, Outcome, Obstacle, Plan) to Dementia Caregivers
SBC: BORROW MY GLASSES LLC Topic: NIA1 Approximately 6.5 million Americans aged 65 and older live with dementia, supported by more than 11 million2 unpaid family caregivers. These numbers are projected to rise exponentially in the coming decades fueling the3 need to develop scalable ways to support dementia caregivers. The need to empower dementia caregivers to4 continue providing care while maintaining their own health and well-bein ...
STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health -
Topical Eyedrops Increasing Lysyl Oxidase Activity to Control Myopia
SBC: Iveena Delivery Systems, Inc. Topic: NEIProject Summary Pediatric myopia, also known as nearsightedness, is an eye condition in which one is unable to bring distant objects into proper focus. It is the leading cause of vision impairment in the world. The estimated economic impact of uncorrected refractive error is estimated to be a loss of $202 billion of global gross domestic product. The prevalence of myopia and high myopia are increa ...
SBIR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health -
Computational Infrastructure for Automated Force Field Development and Optimization
SBC: ATTMOS Inc. Topic: 400Project AbstractOur overarching goal is to provide reliable and efficient tools that can be used in structure based drug discovery (SBDD). One crucial component of SBDD is to predict the structure of a drug molecule that binds to a protein involved in a certain disease. This is usually achieved using computer tools and the process consists of two steps, namely hit identification and lead optimizat ...
SBIR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health -
Modular Virtual Reality Therapeutic for Opioid and Stimulant Use Disorders
SBC: INNATEVR LLC Topic: NIDAPROJECT SUMMARY Opioid and/or Stimulant Use Disorders (OUD/StUD) are chronic, recurring conditions that if left untreated, pose a significant and ongoing public health and safety threat, with costs associated with OUD alone in the US exceeding one trillion dollars annually. Virtual Reality Cue Exposure (VRCE) employs safe and controlled repeated exposure to a variety of substance use cues and envi ...
SBIR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health -
Engineering next generation supercharged CAR T-cells against solid tumors
SBC: Cellinfinity Bio, Inc. Topic: 102Project summary Adoptive cell therapy has revolutionized cancer treatment and has immense potential to cure a variety of cancer types. Multiple critical barriers exist for current CAR-T therapy particularly in solid tumor, including insufficient T cells trafficking to the cancer site, lack of effective cancer cell killing, severe toxicity, strong immunosuppression in the tumor microenvironment, an ...
SBIR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health -
A Precision Medicine for Alcohol-Associated Liver Disease
SBC: GENETOBE INC Topic: 150ABSTRACT The goal of this study is to develop an RNAi-based genetic precision medicine to treat alcohol associated liver disease (AALD). AALD is a devastating health problem worldwide, accounts for the majority of alcohol-related mortality globally and is the second most indication for liver transplantation in the US. The current medical management for AALD remains limited, and no proven pathobiol ...
STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health -
A Potent D-peptide Inhibitor of TNFα for Treatment of Rheumatoid Arthritis
SBC: D BioTherapeutics, LLC Topic: NIAMSRheumatoid arthritis (RA) is a chronic, debilitating inflammatory disease with high medical and societal costs afflicting more than 1.6 million Americans. Blockade of TNFα-driven inflammation with approved anti-TNFα biologics (such as Humira®, Remicade®, Simponi®, and Enbrel®) is an effective treatment for many patients suffering from RA. However, due at least in part to the immunogenicity o ...
SBIR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health -
Multisensory Augmented Reality as a bridge to audio-only accommodations for inclusive STEM interactive digital media
SBC: ALCHEMIE SOLUTIONS, INC. Topic: 500Only 3% of individuals who are blind or have low vision (BLV) have been employed in a STEM field. The lack of accessible accommodations to visually rich dynamic STEM content creates roadblocks to success for BLV students in STEM education throughout their academic journey. The goal of this SBIR is a usable system of accommodations for Interactive Digital Media (IDM), so students with profound visu ...
SBIR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health -
A novel platform for synthetic generation and statistical obfuscation of tabular clinical data, simulated images, and machine-generated text
SBC: GRAYRAIN, LLC Topic: NCATSPROJECT SUMMARY Data is a critical and highly valuable commodity, driving meaningful change in our society, especially when it pertains to patient care and biomedical research. Currently, institutions pay inordinate sums to increase, regain, and complement their data panels. As an extra burden, data legislation and privacy protection regulations introduce barriers to forming effective partnerships ...
STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health -
PANK Activators for the treatment of pantothenate kinase-associated neurodegeneration
SBC: Virtus Therapeutics Corporation Topic: NINDSSUMMARY Pantothenate kinase-associated neurodegeneration, PKAN, is a rare progressive neurodegenerative disorder associated with iron accumulation in the brain. The disease causes early immobility and often death by early adulthood. PKAN is caused by mutations in one of four human pantothenate kinase genes, PANK2 gene, which encodes a mitochondrial pantothenate kinase. Consistent with the clinical ...
SBIR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health